Login to Your Account



Potential $340M Partnership

Sickle Cell Crisis Drug Lands Pfizer Deal for GlycoMimetics

By Jennifer Boggs


Wednesday, October 12, 2011
Privately held GlycoMimetics Inc. landed its first big pharma partnership, licensing rights to pan-selectin antagonist GMI-1070 to Pfizer Inc. for further development in the orphan indication of sickle cell crisis, as well as other indications.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription